Chugai Pharmaceutical Co., Ltd.
Stock Price Chart
2026/05/11 UpdatedPrice Trend
2026/05/11 UpdatedPrice & Trading Details
2026/05/11 UpdatedPRICE
TRADING
Analyst Recommendations 15 analysts
Updated 2026/05/01Earnings Calendar
Updated 2026/05/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/04/24 | ¥68.59 | ¥70.13 | +2.3% |
| 2026/01/28 | ¥72.09 | ¥78.02 | +8.2% |
| 2025/10/24 | ¥73.28 | ¥67.58 | -7.8% |
| 2025/07/24 | ¥75.76 | ¥59.04 | -22.1% |
Shareholder Composition
Updated 2026/05/01Top Mutual Funds / ETFs
Updated 2026/05/01Major Holders
Updated 2026/05/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
9.4M | +0.87% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
7.9M | -4.44% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
6.0M | +2.04% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
5.1M | -10.17% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
4.7M | +1.25% | |
|
NEW PERSPECTIVE FUND
|
4.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
5.3K | -3.20% |
Dividend History 4Years Growth
Updated 2026/05/10| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥272 | +177.6% |
| 2024 | ¥98 | +22.5% |
| 2023 | ¥80 | +2.6% |
| 2022 | ¥78 | +2.6% |
| 2021 | ¥76 | - |
Financial Performance
2026/05/10 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥999,758M | ¥1,259,726M | ¥1,111,367M | ¥1,170,611M |
| Gross Profit | ¥661,612M | ¥783,475M | ¥698,061M | ¥831,201M |
| Operating Income | ¥421,897M | ¥533,308M | ¥439,174M | ¥542,002M |
| Pretax Income | ¥419,433M | ¥531,227M | ¥443,848M | ¥542,002M |
| Net Income | ¥302,995M | ¥374,429M | ¥325,472M | ¥387,317M |
| EPS | ¥184.17 | ¥227.57 | ¥197.80 | ¥235.36 |
| Operating Margin | 42.20% | 42.34% | 39.52% | 46.30% |
| Balance Sheet | ||||
| Total Assets | ¥1,538,694M | ¥1,869,758M | ¥1,932,547M | ¥2,208,373M |
| Total Equity | ¥1,188,017M | ¥1,424,387M | ¥1,625,580M | ¥1,901,499M |
| Total Liabilities | ¥350,677M | ¥445,371M | ¥306,967M | ¥306,874M |
| Cash | ¥267,753M | ¥222,169M | ¥458,674M | ¥540,202M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 77.21% | 76.18% | 84.12% | 86.10% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥279,626M | ¥243,582M | ¥409,925M | ¥447,600M |
| Investing CF | -¥118,927M | -¥145,465M | -¥37,290M | -¥227,365M |
| Financing CF | -¥107,408M | -¥145,641M | -¥139,331M | -¥141,006M |
| Free CF | ¥206,760M | ¥172,343M | ¥335,667M | ¥392,701M |
| Efficiency | ||||
| ROE | 25.50% | 26.29% | 20.02% | 20.37% |
| ROA | 19.69% | 20.03% | 16.84% | 17.54% |
Latest IR Information
-
Fiscal Year Ending December 2026 Q1 Consolidated Financial Results [IFRS] Supplementary Materials
In the first quarter of the fiscal year ending December 2026, revenue was 321.7 billion yen (YoY +11.5%), operating income was 158.8 billion yen (YoY +16.2%), and net income attributable to owners of parent was 115.4 billion yen (YoY +18.7%),...
Read more -
Notice on the Finalization of Details for Share Acquisition Accompanying the Introduction of the Trust-Type Stock Compensation Plan
Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market between May 1 and the end of May 2026, in conjunction with the introduction of a trust-type stock compensation plan.
Read more -
Q1 Financial Summary for the Fiscal Year Ending December 2026 [IFRS] (Consolidated)
In Q1 of the fiscal year ending December 2026, revenue reached JPY 321.7 billion (11.5% YoY increase), operating income was JPY 158.8 billion (16.2% YoY increase), and quarterly profit was JPY 115.4 billion (18.7% YoY increase). The number of outstanding...
Read more -
F. Hoffman-La Roche's Sales Performance for Q1 2026
F. Hoffman-La Roche announced its sales performance for January–March 2026. The parent company of Chugai Pharmaceutical, Roche Holding AG, holds 59.89% of the company’s shares.
Read more -
Matters Concerning Controlling Shareholders
The parent company, Roche Holding Limited, holds 61.12% of voting rights, maintaining management independence while continuing a strategic alliance. Roche nominates fewer than half of the directors, and a special committee is established to protect minority shareholders.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥10,137
Rating Score: 2.07 (Based on 15 analysts)
※1=Strong Buy, 5=Strong Sell
MSN Money - MSN ↗
Company Information
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
